1. European Medicines Agency (EMA). ICH Q5E, CPMP/ICH/5721/03. Comparability of biotechnological/biological products: note for guidance on biotechnological/biological products subject to changes in their manufacturing process. [Consulté en juillet 2019. Disponible sur : www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000888. jsp&mid=WC0b01ac058002956b]
2. Introduction à la médecine expérimentale;Bernard,1865
3. Community oncologists’ perception and understanding of biosimilars’ role in oncology;Nabhan;J Clin Pathways,2018
4. Judgment under uncertainty: heuristics and biases;Tversky;Science,1974
5. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab;Tweehuysen;Arthritis Rheumatol,2018